A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease
Open Access
- 14 January 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (2) , 525
Abstract
In April 2012, a group of nephrologists organized a consensus conference in Cambridge (UK) on type II membranoproliferative glomerulonephritis and decided to use a new terminology, “C3 glomerulopathy” (C3 GP). Further knowledge on the complement system and on kidney biopsy contributed toward distinguishing this disease into three subgroups: dense deposit disease (DDD), C3 glomerulonephritis (C3 GN), and the CFHR5 nephropathy. The persistent presence of microhematuria with or without light or heavy proteinuria after an infection episode suggests the potential onset of C3 GP. These nephritides are characterized by abnormal activation of the complement alternative pathway, abnormal deposition of C3 in the glomeruli, and progression of renal damage to end-stage kidney disease. The diagnosis is based on studying the complement system, relative genetics, and kidney biopsies. The treatment gap derives from the absence of a robust understanding of their natural outcome. Therefore, a specific treatment for the different types of C3 GP has not been established. Recommendations have been obtained from case series and observational studies because no randomized clinical trials have been conducted. Current treatment is based on corticosteroids and antiproliferative drugs (cyclophosphamide, mycophenolate mofetil), monoclonal antibodies (rituximab) or complement inhibitors (eculizumab). In some cases, it is suggested to include sessions of plasma exchange.Keywords
This publication has 81 references indexed in Scilit:
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- C3 glomerulopathy–associated CFHR1 mutation alters FHR oligomerization and complement regulationJournal of Clinical Investigation, 2013
- A Hybrid CFHR3-1 Gene Causes Familial C3 GlomerulopathyJournal of the American Society of Nephrology, 2012
- Eculizumab for Dense Deposit Disease and C3 GlomerulonephritisClinical Journal of the American Society of Nephrology, 2012
- Causes of Alternative Pathway Dysregulation in Dense Deposit DiseaseClinical Journal of the American Society of Nephrology, 2012
- Familial C3 Glomerulopathy Associated with CFHR5 MutationsClinical Journal of the American Society of Nephrology, 2011
- Recurrence of Complement Factor H-Related Protein 5 Nephropathy in a Renal TransplantAmerican Journal of Transplantation, 2011
- Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulationJournal of Clinical Investigation, 2010
- Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritisThe Lancet, 2010
- Disease recurrence in paediatric renal transplantationPediatric Nephrology, 2009